Oct 13 (Reuters) - BioNTech said on Tuesday its experimental mRNA cancer immunotherapy failed to meet the first main goal of ...

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 ...

Top US experts on Timesnownews.com - From geopolitics to AI to lifestyle, get the views from the best in the world.

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

Moderna, Inc. was added back to the Nasdaq-100 index and earlier announced that former manufacturing leader Juan Andres would ...

Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and ...

Explore the potential of a personalized mRNA vaccine that targets specific cancer mutations for advanced melanoma treatment.

A new mRNA flu vaccine promises a closer match to circulating flu strains. But dysfunction at federal health agencies is ...

How delivery plays a new role as the key to success in mRNA application across therapeutic approaches For much of the past ...

The FDA has approved mFlusiva, the first mRNA flu vaccine, for adults ages 50 to 64, but the CDC has not added it to its recommended list amid legal uncertainties and disruptions to the federal ...

Denise Fitzsimmons knew that removing the fast-growing lump above her eyebrow in 2024 didn’t eliminate the possibility that her melanoma could return. But a clinical trial at Penn Medicine offered the ...

People looking to get their annual flu shot this fall may find a new option alongside the usual vaccines: an mRNA flu shot. Not everyone is eligible, however.